About Novo Ventures

Since 2000, when Novo started to build its investment portfolio, the venture activities in Novo have matured and Novo is now recognised as a significant force within life science venture capital – operating globally out of locations in Copenhagen, London and San Francisco. By now, more than 57 companies have been part of the evolving venture portfolio in Novo A/S.

Novo A/S’ approach to venture capital investments is unique due to its special ownership structure. Although Novo owns significant shareholdings in Novo Nordisk A/S and Novozymes A/S, its venture investments are fully independent of the two major Novo Group companies.

Novo’s venture investments are structured as an ‘open evergreen’ fund with a single investor. This unique funding structure allows Novo to take a long-term perspective in its investments and also has the advantage that it precludes some of the restrictions to which traditional venture capital funds are subject, for instance when they pursue investments in the interim between a fully vested and a newly raised fund.

Click here to read the article from the Annual Report 2008 on 'State of the biotech industry and its key challenges' as addressed at Novo's BioSummit 2008.

Click here to download Novo Ventures' brochure.

Click here to download Novo Ventures' brochure addendum.